Introduction {#s1}
============

Patients with glioblastoma have a poor prognosis with a median overall survival of 10--15 months, despite safe and maximal surgical resection followed by chemo- and radiotherapy ([@B1]). This prognosis varies based on known factors such as age, KPS, extent of resection, isocitrate dehydrogenase (IDH) mutation status, and methylguanine methyltransferase (MGMT) promoter methylation status ([@B2], [@B3]).

Maximal resection of the contrast enhanced (CE) portion of glioblastoma has been associated with better overall survival and is currently part of standard surgical glioblastoma treatment ([@B3]). However, glioblastoma is known to infiltrate far beyond the margins of CE as seen on MRI, into the surrounding non-contrast enhanced (NCE) edematous T2-weighted or FLAIR abnormality area ([@B4]). This raises the question whether maximal CE tumor resection should be extended beyond CE, into NCE area, to improve survival ([@B5]). A recent meta-analysis and a systematic review suggested that there is an association between maximal CE tumor resection with resection of NCE tumor and overall survival ([@B5], [@B6]). However, the quality of evidence of the available studies was low due to confounding and selection biases. On top, studies investigating the impact of CE and NCE resection have reported limited molecular data on IDH mutation and MGMT promoter methylation of their studied glioblastoma population ([@B6], [@B7]).

Thus, in light of the WHO 2016 reclassification, which now includes such molecular data, the association between CE and NCE glioblastoma resection and survival needs to be re-evaluated in a molecularly homogenous glioblastoma IDH-wildtype population, while considering MGMT promoter methylation ([@B8]). The aim of this study therefore, was to assess the association between CE and NCE tumor resection and survival in light of MGMT promoter methylation in a cohort of patients with newly diagnosed IDH-wildtype glioblastoma.

Materials and Methods {#s2}
=====================

Patients
--------

All consecutive patients aged 18 years or older, newly diagnosed with a CE mass lesion as seen on post-contrast T1-weighted MRI scans, histopathological confirmed as IDH-wildtype glioblastoma, who underwent tumor resection or biopsy between January 2012 and May 2018 at Erasmus Medical Center Rotterdam were considered for this retrospective study. Patients were eligible if pre- and immediate post-operative (\<48 h) T2-weighted or FLAIR and post-contrast T1-weighted MRI scans were available together with complete molecular data on IDH mutation and MGMT methylation. Molecular analysis was *post-hoc* performed in patients with unknown IDH mutation or MGMT methylation status; patients without enough tumor material for molecular analysis or in whom assays failed to produce a test result were excluded. The study was approved by the Medical Ethical Committee of Erasmus Medical Center Rotterdam, who waived the need for written informed consent from the patients due to the retrospective nature of this study and the (emotional) burden that would result from contacting the patients or their relatives to obtain consent. The study was performed in accordance with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards and reported following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines.

Image Acquisition, Tumor Segmentation, and Extent of Resection
--------------------------------------------------------------

From pre- and post-operative MRI scans, which were obtained in the clinical routine either on a 1.5T or 3.0T scanner, post-contrast T1-weighted and T2-weighted or FLAIR images were collected.

For glioblastoma segmentation, we imported both pre- and post-operative post-contrast T1-weighted and T2-weighted or FLAIR scans into Brainlab (BrainLab, Feldkirchen, Germany, version 2.1.0.15). Using the SmartBrush tool in Brainlab Elements, we semi-automatically segmented all tumor involved CE on pre-operative post-contrast T1-weighted scans (including the necrotic part, if present) and all tumor involved CE on post-operative post-contrast T1-weighted scans (excluding small vessels in the surgical cavity or hemorrhage). We then semi-automatically segmented all tumor-related NCE on both pre-and post-operative T2-weighted or FLAIR scans (excluding extra-lesional hemorrhage). We attempted to minimize the inclusion of surgery induced new T2-weighted or FLAIR abnormality by overlaying and carefully comparing pre- and post-operative MRIs. We manually corrected all segmentations when needed using the manual Brush tool. All tumor volumes were assessed while being blinded for patients\' clinical outcome.

We finally obtained four tumor volumes (cm^3^): pre-operative and residual CE volumes and pre-operative and residual NCE volumes. We calculated the CE surrounding NCE volumes by subtracting CE volumes from the total NCE volumes. We calculated the extent of resection (EOR, %) separately for both the CE and NCE portion with the formula: \[(pre-operative volume -- residual volume)/pre-operative volume\] ^\*^ 100 ([@B9]). Maximal CE resection was categorized in our dataset as CE EOR \>97%. NCE tumor resection was dichotomized into ≥30% resection and \<30% resection based on threshold analyses ([Figures S1](#SM1){ref-type="supplementary-material"}, [S2](#SM2){ref-type="supplementary-material"}) and analyzed independently from CE tumor resection (i.e., irrespective of whether complete CE tumor resection was achieved or not). Tumors that were biopsied were segmented only on pre-operative MRI scans and their EOR was imputed as being 0%. In addition to the CE EOR categories (biopsy, subtotal, maximal resection), we categorized CE residual tumor volumes in \>5, 1--5, and 0--1 cm^3^. While CE EOR is in part defined by CE residual tumor volume (as given by the above-mentioned EOR formula), the categories are not identical due to variations in pre-operative tumor volume.

Molecular Analysis
------------------

Tumor tissue samples were obtained from patients through surgical resection or biopsy. Histopathological examination was performed by neuropathologists; IDH mutational analysis was assessed with Sanger sequencing or targeted next generation sequencing and MGMT methylation status was assessed with a methylation specific PCR, as described elsewhere ([@B10]--[@B12]).

Statistical Analysis
--------------------

Overall survival was defined as time from surgery to death (primary outcome) and progression-free survival (PFS) was defined as time from surgery till clinical or radiological progression (secondary outcome). Patients were censored at time of last clinical follow up date.

Statistical analyses were performed with SPSS 25.0 statistical software (IBM Corp.). Pre-operative and post-operative residual tumor volume distributions were skewed and therefore log transformed prior to statistical analysis. Descriptive statistics were tested between MGMT methylation status groups with the Chi Squared Test or Fisher Exact test in case of categorical variables, with the Kruskal Wallis test in case of continuous non-normal distributed data and with log rank tests to compare median overall survival and PFS when using Kaplan Meier analysis.

The associations between each variable and outcome were first tested with univariable Cox proportional hazards models and all variables with *p* \< 0.10 (entry significance threshold) were selected for multivariable Cox proportional hazards models. These models were stratified for MGMT, because this variable violated the proportional hazards assumption. Hazard ratio (HR) with 95% Confidence interval (CI) was estimated for each variable within the model. A *p* \< 0.05 was considered statistically significant.

Results {#s3}
=======

There were 375 glioblastoma patients considered for this study. We excluded 36 (9.6%) due to insufficient tissue material for molecular analysis, and 13 (3.5%) because of the presence of IDH mutation. In total, 326 IDH-wildtype glioblastoma were included in our analysis: 177 (54.3%) with and 149 (45.7%) without MGMT promoter methylation. Maximal CE resection was achieved in 61 patients (18.7%), while in 187 (57.4%) patients maximal resection of CE could not be achieved. Seventy-eight patients (23.9%) underwent biopsy. In 156 (47.9%) patients, ≥30% NCE tumor resection was achieved and in 170 (52.1%) patients 0--30% NCE tumor resection was achieved. Median overall survival and PFS was 309 days (95% CI, 278--340) and 174 days (95% CI, 159--209), respectively. Further patient and tumor characteristics are presented in [Table 1](#T1){ref-type="table"}.

###### 

Patient and tumor characteristics.

  **Characteristics**                                                                             **MGMT promoter**                                        
  ------------------------------------------------------------ -------------------- ------------- -------------------- ------- -------------------- ------ -----------
                                                               326                  100           177                  54.3    149                  45.7   
  **Sex**                                                                                                                                                  **0.006**
  Male                                                         206                  63.2          100                  48.5    106                  51.5   
  Female                                                       120                  36.8          77                   64.2    43                   35.8   
  **Age, Years**                                                                                                                                           0.122
  ≤ 65                                                         162                  49.7          81                   50.0    81                   50.0   
  \>65                                                         164                  50.3          96                   58.5    68                   41.5   
  Mean, years (*SD*)                                           63.8 (10.5)                        64.2 (10.9)                  63.3 (10.1)                 0.453
  **KPS**                                                                                                                                                  0.748
  ≤ 70                                                         119                  36.5          66                   55.5    53                   45.5   
  \> 70                                                        207                  73.5          111                  53.6    96                   46.4   
  Mean (*SD*)                                                  79.2 (12.4)          78.8 (12.2)   79.7 (12.6)          0.480                               
  **Pre-operative Tumor Volume, Median cm**^**3**^ **(IQR)**                                                                                               
  CE                                                           34.9 (15.5--55.8)                  30.7 (13.8--52.5)            39.9 (17.1--26.2)           0.050
  NCE                                                          72.1 (29.4--127.5)                 78.1 (27.8--133.8)           64.9 (32.3--113.4)          0.249
  **Residual Tumor Volume, Median cm**^**3**^ **(IQR)**                                                                                                    
  CE                                                           5.0 (1.41--12.3)                   6.1 (1.8--12.5)              3.8 (1.1--12.0)             0.097
  NCE                                                          39.7 (18.3--73.7)                  42.2 (17.1--79.6)            36.5 (20.4--64.2)           0.699
  **Maximal CE Resection**                                                                                                                                 0.213
  Yes                                                          61                   18.7          27                   44.3    34                   55.7   
  No                                                           187                  57.4          105                  56.2    82                   43.8   
  Biopsy                                                       78                   23.9          45                   57.7    33                   42.3   
  Median EOR (IQR)                                             83.4 (14.2-94.8)                   79.6 (0-91.9)                88.0 (25-7-96.0)            0.075
  **NCE Resection**                                                                                                                                        0.609
  ≥30%                                                         156                  47.9          87                   55.8    69                   44.2   
  \<30%                                                        170                  52.1          90                   52.9    80                   47.1   
  Median EOR (IQR)                                             27.1 (0--57.1)                     28.7 (0--58.4)               25.8 (0--55.0)              0.948
  **Adjuvant Therapy**                                                                                                                                     0.294
  No therapy                                                   61                   18.7          38                   62.3    23                   37.7   
  Radio- or chemotherapy alone                                 56                   17.2          27                   48.2    29                   51.8   
  Chemoradiation                                               209                  64.1          112                  58.4    97                   41.6   
  **Overall Patient Outcome**                                                                                                                              
  Median overall survival (95% CI)                             309 (278.0--340.0)                 334 (266.8--401.2)           305 (275.2-334.8)           **0.003**
  Median progression-free survival (95% CI)                    184 (159.3--208.7)                 174 (131.2--216.8)           190 (162.0--218)            0.053

*MGMT, methylguanine methyltransferase; SD, standard deviation; CE, contrast enhancement; NCE, non contrast enhancement; EOR, extent of resection; IQR, Inter Quartile Range; CI, Confidence interval*.

Univariable Cox proportional hazards regression analysis identified age ≤ 65y (HR 0.64; 95% CI, 0.51--0.80; *p* \< 0.0001), KPS \>70 (HR 0.59; 95% CI, 0.47--0.74; *p* \< 0.0001), MGMT promoter methylation (HR 0.72; 95% CI, 0.57--0.90; *p* \< 0.004), adjuvant chemoradiation (HR 0.14; 95% CI, 0.11--0.19; *p* \< 0.0001), smaller pre-operative CE tumor volumes (per cm^3^ HR 0.92; 95% CI, 0.83--1.01; *p* \< 0.094), maximal CE tumor resection (HR 0.51; 95% CI, 0.36--0.72; *p* \< 0.0001), and ≥30% NCE tumor resection (HR 0.72; 95% CI, 0.58--0.91; *p* = 0.005) as being associated with longer overall survival. As further presented in [Table 2](#T2){ref-type="table"}, the variables age ≤ 65y, KPS \> 70, adjuvant chemoradiation, maximal CE resection, and ≥30% NCE tumor resection were also significantly associated with a longer PFS in univariable Cox regression analysis (*p* \< 0.05). Kaplan Meier curves for overall survival and PFS for each variable are presented in [Figure S3](#SM3){ref-type="supplementary-material"}.

###### 

Cox proportional hazards models for overall survival and progression-free survival.

  **Variable**                        **Median days, 95%CI**                  **Overall survival**                              **Median days, 95%CI**             **Progression-free survival**                                                                                                                                
  ----------------------------------- --------------------------------------- ---------------------------------- -------------- ---------------------------------- ------------------------------- --------------------------------------- ---------------------------------- -------------- ---------------------------------- --------------
  **Age, years**                                                                                                                                                                                                                                                                                                                
  \>65                                259, 191--327                           [^a^](#TN1){ref-type="table-fn"}                                                                                     144, 114--175                           [^a^](#TN1){ref-type="table-fn"}                                                     
  ≤ 65                                358, 311--405                           0.64, 0.51--0.80                   **\<0.0001**   0.63, 0.49--0.81                   **\<0.0001**                    216, 181--251                           0.70, 0.56--0.89                   **0.003**      0.82, 0.64--1.06                   0.123
  **KPS**                                                                                                                                                                                                                                                                                                                       
  ≤ 70                                199, 142--256                           [^a^](#TN1){ref-type="table-fn"}                                                                                     120, 91--149                            [^a^](#TN1){ref-type="table-fn"}                                                     
  \>70                                369, 319--419                           0.59, 0.47--0.74                   **\<0.0001**   0.92, 0.71--1.19                   0.545                           223, 181--265                           0.51, 0.40--0.65                   **\<0.0001**   0.59, 0.45--0.77                   **\<0.0001**
  **MGMT Promoter**                                                                                                                                                                                                                                                                                                             
  Unmethylated                        305, 275--335                           [^a^](#TN1){ref-type="table-fn"}                  [^b^](#TN2){ref-type="table-fn"}                                   190, 162--218                           [^a^](#TN1){ref-type="table-fn"}                  [^b^](#TN2){ref-type="table-fn"}   
  Methylated                          334, 267--401                           0.72, 0.57--0.90                   **0.004**                                                                         174, 131--217                           0.79, 0.62--1.00                   **0.054**                                         
  **Adjuvant Therapy**                                                                                                                                                                                                                                                                                                          
  None                                65, 46--84                              [^a^](#TN1){ref-type="table-fn"}                                                                                     47, 38--56                              [^a^](#TN1){ref-type="table-fn"}                                                     
  Radiotherapy or chemotherapy        217, 146--288                           0.38, 0.26--0.55                   **\<0.0001**   0.29, 0.19--0.43                   **\<0.0001**                    129, 107--151                           0.23, 0.15--0.36                   **\<0.0001**   0.22, 0.14--0.35                   **\<0.0001**
  Chemoradiation                      423, 367--479                           0.14, 0.11--0.19                   **\<0.0001**   0.13, 0.09--0.19                   **\<0.0001**                    254, 222--287                           0.09, 0.06--0.13                   **\<0.0001**   0.09, 0.06--0.14                   **\<0.0001**
  **Pre-operative CE Tumor Volume**                                                                                                                                                                                                                                                                                             
  smaller per cm^3^                                                           0.92, 0.83--1.01                   **0.094**      0.85, 0.75--0.95                   **0.007**                                                               0.94, 0.85--1.04                   0.239          0.99, 0.88--1.11                   0.860
  **Maximal CE Resection**            **[^\*^](#TN4){ref-type="table-fn"}**                                                                                                                        **[^\*^](#TN4){ref-type="table-fn"}**                                                                                        
  Biopsy                              153, 106--200                           [^a^](#TN1){ref-type="table-fn"}                                                                                     100, 87--113                            [^a^](#TN1){ref-type="table-fn"}                                                     
  No                                  309, 278--340                           0.79, 0.60--1.04                   **0.090**      0.87, 0.61--1.23                   0.415                           190, 170--210                           0.80, 0.61--1.05                   0.109          1.25, 0.89--1.81                   0.228
  Yes                                 441, 321--560                           0.51, 0.36--0.72                   **\<0.0001**   0.58, 0.39--0.87                   **0.009**                       272, 210--334                           0.59, 0.42--0.85                   **0.004**      0.97, 0.63--1.50                   0.898
  **NCE Resection**                   **[^\*^](#TN4){ref-type="table-fn"}**                                                                                                                        **[^\*^](#TN4){ref-type="table-fn"}**                                                                                        
  \<30%                               266, 213--319                           [^a^](#TN1){ref-type="table-fn"}                                                                                     155, 104--206                           [^a^](#TN1){ref-type="table-fn"}                                                     
  ≥30%                                344, 304--385                           0.72, 0.58--0.91                   **0.005**      0.71, 0.53--0.93                   **0.014**                       203, 166--240                           0.82, 0.65--1.03                   **0.087**      0.87, 0.65--1.15                   0.325

*Reference group*.

*Proportional hazard assumption for MGMT was violated, therefore multivariable Cox regression model was stratified for MGMT*.

*HR, Hazard ratio; MGMT, methylguanine methyltransferase, CI Confidence Interval*.

*for MGMT-stratified median overall survival, see [Figure 1](#F1){ref-type="fig"}*.

*entry significance threshold of p \< 0.1*.

*significance threshold of p \< 0.05*.

Multivariable Cox proportional hazards regression analysis stratified for MGMT methylation status and risk adjusted for age ≤ 65y (HR 0.63; 95% CI, 0.49--0.81; *p* \< 0.0001), KPS \> 70 (HR 0.92; 95% CI, 0.71--1.19; *p* = 0.545), adjuvant chemoradiation (HR 0.13; 95% CI, 0.09--0.19; *p* \< 0.0001), and smaller pre-operative CE tumor volumes per cm^3^ (HR 0.85; 95% CI, 0.75--0.95; *p* = 0.007) identified maximal CE tumor resection (HR 0.58; 95% CI, 0.39--0.87; *p* = 0.009) and ≥30% NCE tumor resection (HR 0.71; 95% CI, 0.53--0.93; *p* = 0.014) as being associated with longer overall survival ([Table 2](#T2){ref-type="table"}). Variables that remained significantly associated with a longer PFS were KPS \> 70 (HR 0.59; 95% CI, 0.45--0.77; *p* \< 0.0001) and adjuvant chemoradiation (HR 0.09; 95% CI, 0.06--0.14; *p* \< 0.0001). Explorative multivariable Cox proportional hazards regression analyses showed that higher NCE tumor resection thresholds (e.g., ≥50%) were not associated with a favorable overall survival (*p* \> 0.05) (for threshold analysis, see [Figure S1](#SM1){ref-type="supplementary-material"}).

Kaplan Meier estimates suggested that the impact of maximal CE tumor resection was more beneficial for patients with MGMT methylated glioblastoma and that it significantly improved median overall survival (572 days; 95% CI, 424--720), when compared to STR (342 days; 95% CI, 282--402; *p* = 0.014) or biopsy (112 days; 95% CI, 36--42; *p* = 0.001) ([Figure 1A](#F1){ref-type="fig"}). Patients with MGMT methylated glioblastoma also had a longer overall survival with ≥30% NCE tumor resection (425 days; 95% CI, 286--564) than with \<30% NCE tumor resection (190 days; 95% CI, 107--273; *p* = 0.001) ([Figure 1B](#F1){ref-type="fig"}). In patients with MGMT unmethylated glioblastoma, no survival benefit was observed with ≥30% NCE resection (*p* = 0.884).

![Overall and MGMT-stratified Kaplan Meier curves for overall survival **(A)** Maximal CE resection **(B)** NCE resection and **(C)** CE residual volume.](fonc-10-01087-g0001){#F1}

We further assessed minimal post-operative CE residual volumes with a potential positive impact on overall survival. In MGMT methylated glioblastoma, when compared to \>5 cm^3^ residual CE tumor (224 days; 95% CI 164--284), we observed a significantly longer median overall survival for a residual CE tumor volume of 1--5 cm^3^ (470 days; 95% CI 330--610; *p* \< 0.0001) and 0--1 cm^3^ (536 days; 95% CI 319--752; *p* = 0.003) ([Figure 1C](#F1){ref-type="fig"}). In MGMT unmethylated glioblastoma, we only observed a longer overall survival in residual CE volumes of 0--1 cm^3^ (427 days; 95% CI, 350--503), when compared to 1--5cm^3^ (299 days; 95% CI, 270--327; *p* = 0.006) or to \>5 cm^3^ (200 days; 95% CI, 102--298; *p* = 0.003) ([Figure 1C](#F1){ref-type="fig"}). In these tumors, no difference in median overall survival was observed between 1--5 and \>5 cm^3^ (*p* = 0.371) residual CE tumor volume. Multivariable Cox proportional hazards regression analysis stratified for MGMT and adjusted for age, KPS, adjuvant chemoradiation, and pre-operative CE tumor volume, identified a residual CE tumor volume of 0--1 cm^3^ (HR 0.64; 95% CI, 0.46--0.88 *p* = 0.007), and 1--5 cm^3^ (HR 0.71; 95% CI, 0.54--0.94; *p* = 0.016) as being associated with favorable overall survival. These analyses were also performed for post-operative residual NCE volumes, but here no minimal volume threshold with a positive impact on overall survival was identified.

Discussion {#s4}
==========

This study shows an association between maximal CE tumor resection, ≥30% NCE tumor resection, minimal residual CE tumor volume and longer overall survival in 326 patients with newly diagnosed IDH-wildtype glioblastoma. We observed that extensive resection was more beneficial for patients with MGMT methylated IDH-wildtype glioblastoma in terms of survival.

Maximal resection of CE has earlier been associated with longer overall survival in a large meta-analysis of neurosurgical literature based on 37 studies and 41,117 unique glioblastoma patients ([@B3]). This association has recently been re-evaluated based on two new insights. First, studies performed before the WHO 2016 reclassification have included limited molecular data, because the impact of molecular subtyping of glioblastoma according to IDH mutation status was less of a consideration ([@B3], [@B7], [@B13]--[@B15]). Although IDH mutation within newly diagnosed primary glioblastoma is rare (\<5 and 3.5% in our cohort) these tumors represent a distinct molecular type of glioma arising from a distinct precursor lesion ([@B16], [@B17]). Therefore, incomplete or absence of molecular data on IDH mutation and MGMT methylation or mixing molecular subtypes when evaluating the impact of glioblastoma resection on survival is undesirable. More recent studies did investigate the impact of glioblastoma surgery on survival in light of molecular markers. A recent study investigated the impact of maximal CE resection and MGMT promoter methylation status in a homogenous IDH-wildtype glioblastoma population (*n* = 175) and showed that both were significantly associated with longer overall survival ([@B2]). Ellingson et al. showed in 1,054 glioblastoma patients (with partially available data on IDH mutation and MGMT methylation) that smaller residual CE tumor volumes (\<12 cm^3^) and MGMT methylation were significantly associated with longer overall survival in patients receiving chemoradiation ([@B18]). A recent study published by Molinaro et al. confirmed the association between maximal CE resection and overall survival across all molecular subgroups of glioblastoma ([@B19]).

Secondly, the association between glioblastoma resection and overall survival is also being reassessed by evaluating the value of NCE tumor resection, because it is known that glioblastoma infiltrates beyond the margins of CE into the NCE area ([@B4]). This aspect of glioblastoma surgery is also recently investigated by Molinaro et al. ([@B19]). The authors found that maximal resection of CE and NCE tumor was associated with longer overall survival in younger patients with IDH wildtype glioblastoma regardless of MGMT methylation status (subset of 190 patients with known IDH mutation and MGMT methylation status). In their study, maximal NCE resection that was associated with overall survival was defined as 92% NCE tumor resection after maximal CE tumor resection. Other studies have associated lower NCE tumor resection thresholds of 53% and 45% with overall survival ([@B7], [@B20]). We observed that a NCE tumor resection threshold of 30% was associated with overall survival. This association was studied CE tumor resection (i.e., irrespective of whether patients did or did not undergo complete CE tumor resection). In exploratory threshold analysis, higher thresholds (e.g., minimal ≥60% NCE tumor resection) seemed not to be associated with overall survival anymore. This may suggest that resection of NCE tumor immediately surrounding CE improves survival, but extending the resection on further distance from CE into NCE tumor does not provide survival benefit. It can be hypothesized that the direct peritumoral NCE area reflects a higher degree of tumor infiltration than the NCE area further away from the CE tumor, which is presumably more dominated by edema than tumor infiltration ([@B4]). In future research, a combination of physiological imaging modalities (such as MR spectroscopy, diffusion and perfusion imaging or positron-emission tomography) may be used to more accurately detect tumor infiltrated portions in NCE and to tailor surgical planning ([@B21]).

Importantly, maximal tumor resection should not be attempted at all cost. Previous studies assessing the value of extensive tumor resection generally reported no or only limited data on eloquent tumor location, neurological outcome or quality of patient life ([@B3], [@B22], [@B23]). The safety of extensive tumor resection is thus mostly unknown and should only be attempted with intraoperative imaging guidance and/or awake surgery with stimulation mapping, especially when tumors are closely related to eloquent brain area ([@B24]). While frontal or temporal pole tumor can commonly be removed more safely, posterior frontal or parietal tumors should be approached with more caution ([@B25], [@B26]).

In line with this, one limitation of this retrospective study is that we did not have sufficient data on eloquent tumor location or neurological outcome of patient after surgery. Therefore, the safety of extensive resection needs further investigation before clinical recommendations and the translation of potential survival benefits, into real world clinical practice can be made. Another limitation of this study is its retrospective nature. This may have introduced some degree of selection bias. We attempted to limit selection bias by consecutive inclusion of all glioblastoma patients operated upon between 2012 and 2018 in our cohort, including patients with complex glioblastoma localization (crossing midline or deep within the basal ganglia) who underwent diagnostic biopsies. We also performed IDH mutational and MGMT promoter methylation analyses on all glioblastoma included in our cohort. A third limitation is that only one observer assessed both pre- and post-operative tumor volumes. In this context, a stringent assessment of residual volumes in the resection cavity by one observer may explain the relatively low maximal CE resection percentage of 17.8%. Although the interobserver agreement is high for pre-operative volumes, it is known to be relatively low for residual tumor volumes. The intra-observer agreement nevertheless, is known to be high for both pre-operative as residual tumor volumes ([@B9], [@B12]). We have also attempted to limit bias during volumetric assessment by blinding the assessor for patients\' clinical outcome. In future research, our findings need to be validated in an external validation. Ideally, the safety of maximizing tumor resection beyond CE tumor margins should be assessed in well-designed well-powered trials with safety measures as primary endpoint.

To conclude, this study shows an association between maximal CE tumor resection, ≥30% NCE tumor resection, minimal residual CE tumor volume, and longer overall survival in patients with newly diagnosed IDH wildtype glioblastoma. Extensive resection was more beneficial for patients with MGMT methylated glioblastoma. Intraoperative imaging and stimulation mapping may be used to pursue maximal tumor resection during glioblastoma surgery. In future research, the safety aspect of maximizing tumor resection needs to be addressed.
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CE

:   contrast enhancement

IDH

:   isocitrate dehydrogenase

MGMT

:   O^6^-Methylguanine-DNA Methyltransferase

NCE

:   non-contrast enhancement.
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